Clinical trials: EGF-R Positive Non-Small Cell Lung Cancer, open to volunteers
Non Small Cell Lung Cancer, Circulating Tumor Cell
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
clinical trial The goal of this clinical trial is to learn whether the treatment of advanced non-small cell lung cancer with EGFR-TKIs, when combined with bevacizumab in the presence of positive circulating tumor cells in the…
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer
- Trial name
- NCT06557096
- Testing
- Osimertinib 80 MG, Bevacizumab
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Non Small Cell Lung Cancer, RET Gene Mutation
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
This is an open-label, single-arm, dose-escalation, multicenter phase I/II clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003…
- Conditions
- Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer
- Trial name
- PROFILE (NCT06109558)
- Testing
- LMV-12(HE003)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hunan Province Tumor Hospital
EGF-R Positive Non-Small Cell Lung Cancer
The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC
This study aimed to assess the value of dynamic ctDNA monitoring in guiding the development of personalized neoadjuvant treatment strategies for EGFR-mutated NSCLC patients.
- Trial name
- NCT06287593
- Testing
- ctDNA monitoring
- Volunteers
- 300 people
- Sponsor
- Zhejiang University
EGF-R Positive Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)
Phase II Study to Evaluate the Impact of SBRT (Stereotactic Body Radiation Therapy) and/or SRS (Stereotactic Radiosurgery) on Oligoresidual Disease in EGFR Mutation Patients Treated with Osimertinib as First-Line Systemic…
- Conditions
- EGF-R Positive Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion, EGFR Exon 21 Mutation
- Trial name
- CULTRO (NCT05998993)
- Testing
- Stereotactic Body Radiation Therapy SBRT
- Where
- Colombia
- Volunteers
- 35 people
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with chemotherapy prior to surgery, in patients with…
- Trial name
- NCT05132985
- Testing
- Icotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Liaoning Cancer Hospital & Institute
NSCLC, EGFR Gene Mutation
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
This study involves patients with EGFR-mutated NSCLC and asymptomatic brain metastases. This is an open-label, randomized study, comparing the continuation of Osimertinib treatment alone to Osimertinib treatment combined with…
- Conditions
- NSCLC, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05033691
- Testing
- Stereotactic surgery
- Where
- Israel
- Volunteers
- 162 people
- Sponsor
- Hadassah Medical Organization